Search

Search Results

1. Rapid Conversion from Solitary Plasmacytoma with Minimal Skull Marrow Involvement to Symptomatic Multiple Myeloma: a Case Report

   Solitary skull plasmacytoma is an uncommon clinical entity, characterized by localized proliferation of neoplastic monoclonal plasma cells. Solitary...

   Yosuke Kawahara, Masashi Kinoshita, ... Mitsutoshi Nakada in SN Comprehensive Clinical Medicine

   Article 09 January 2023
   

2. Cerebral Infarction as the First Manifestation of Multiple Myeloma and AL Amyloidosis: a Case Report

   Multiple myeloma and AL (amyloid light chain) amyloidosis refer to plasma cell abnormalities, with multiple organs being affected, most commonly the...

   Michail Papantoniou, Iason-Georgios Stamatakis, ... Antonios Tavernarakis in SN Comprehensive Clinical Medicine

   Article 31 January 2023
   

3. Unmasking Infection Risks in Multiple Myeloma: Insights from a Retrospective Analysis

   Multiple myeloma (MM) has witnessed significant therapeutic advancements through the introduction of proteasome inhibitors and immunomodulators,...

   Linu Abraham Jacob, Sabeena K. Choudhary, ... Vivek B M in Indian Journal of Hematology and Blood Transfusion

   Article 25 March 2024
   

4. Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India

   Background

   Survival outcomes for multiple myeloma have improved dramatically since the introduction of novel therapeutic agents. While these drugs are...

   Jyoti Dixit, Pankaj Malhotra, ... Shankar Prinja in Applied Health Economics and Health Policy

   Article 07 March 2024
   

5. Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical thrombosis in patients with lymphoma and multiple myeloma

   Patients diagnosed with lymphoma or multiple myeloma are at elevated risk of venous thromboembolism (VTE). Optimum risk stratification and effective...

   Irene Sánchez Prieto, Isabel Gutiérrez Jomarrón, ... Julio García-Suárez in Journal of Thrombosis and Thrombolysis

   Article Open access 27 April 2024
   

6. Assessment of inter- and intraobserver agreement for META score in distinguishing osteoporotic from multiple myeloma vertebral fractures

   Purpose

   To conduct an independent assessment of inter- and intraobserver agreement for the META score as a tool for differentiating osteoporotic...

   Eduardo Henrique Chiovato Abdala, João Pedro Almeida e Oliveira, ... Carlos Fernando P. S. Herrero in European Spine Journal

   Article 08 May 2024

7. Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions

   Purpose of Review

   Multiple myeloma (MM) is a biologically heterogeneous malignancy with relatively uniform treatment paradigms. This review aims to...

   Mina Meseha, James Hoffman, ... Benjamin Diamond in Current Oncology Reports

   Article Open access 27 April 2024
   

8. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast

   The introduction of novel immunotherapies has transformed the treatment landscape in multiple myeloma (MM). The addition of these agents has...

   Ola Landgren, Omar Nadeem in Advances in Therapy

   Article Open access 16 June 2023

9. Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma

   Background

   The roles of Lenalidomide (Len) and Daratumumab (Dara) in multiple myeloma treatment are well-established, yet their influences on...

   Hongpeng Duan, Qiuhui Jiang, ... Zhijuan Lin in Annals of Hematology

   Article 06 March 2024
   

10. Lymphocyte profile in peripheral blood of patients with multiple myeloma

    Multiple myeloma (MM) is a disease which remains incurable. One of the main reasons is a weakened immune system that allows MM cells to survive....

    Tereza Dekojová, Hana Gmucová, ... Monika Holubová in Annals of Hematology

    Article 04 June 2024
    

11. Pet-radiomics in lymphoma and multiple myeloma: update of current literature

    Purpose

    To provide a comprehensive overview of the current literature on the applications of PET-based radiomics in patients affected by multiple...

    Luca Filippi, Cristina Ferrari, ... Laura Evangelista in Clinical and Translational Imaging

    Article 13 November 2023
    

12. Bone marrow stromal cells dictate lanosterol biosynthesis and ferroptosis of multiple myeloma

    Ferroptosis has been demonstrated a promising way to counteract chemoresistance of multiple myeloma (MM), however, roles and mechanism of bone marrow...

    Hongmei Jiang, Lijuan Wang, ... Zhiqiang Liu in Oncogene

    Article Open access 09 April 2024
    

13. Incidence of thromboembolism and associated factors in multiple myeloma patients treated with immunomodulatory drugs: a retrospective analysis in Belo Horizonte, Brazil

    Purpose

    The use of immunomodulators in the treatment of multiple myeloma (MM) patients has been associated with venous thromboembolism (VTE). Due to...

    Iwyson Henrique Fernandes da Costa, Cristiane Aparecida Menezes de Pádua, ... Adriano Max Moreira Reis in Supportive Care in Cancer

    Article 16 December 2023
    

14. FOXM1 regulates glycolysis and energy production in multiple myeloma

    The transcription factor, forkhead box M1 (FOXM1), has been implicated in the natural history and outcome of newly diagnosed high-risk myeloma (HRMM)...

    Yan Cheng, Fumou Sun, ... Siegfried Janz in Oncogene

    Article Open access 06 July 2022
    

15. The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma

    Multiple myeloma (MM) denotes a cancerous growth characterized by abnormal proliferation of plasma cells. Growing evidence suggests that the...

    Long-Ying Zhu, Qi-Lei Hu, ... Zuo-Jie Li in Discover Oncology

    Article Open access 15 June 2024

16. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel

    Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses in patients with relapsed/refractory multiple myeloma...

    Saurabh Zanwar, Surbhi Sidana, ... Doris K. Hansen in Journal of Hematology & Oncology

    Article Open access 06 June 2024
    

17. Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation

    ¹⁸ F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET) positivity after first-line treatment with autologous stem cell...

    Jakob Nordberg Nørgaard, Niels Abildgaard, ... Fredrik Schjesvold in Leukemia

    Article 11 August 2023
    

18. CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myeloma

    Multiple myeloma (MM) cells effectively escape anti-tumoral immunity to survive in the tumor microenvironment (TME). Herein, we identify...

    Aya Ismael, Allen J. Robinette, ... Francesca Cottini in Leukemia

    Article Open access 20 June 2024
    

19. Predicting cytogenetic risk in multiple myeloma using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI, and spinal diffusion-weighted imaging

    Objectives

    Cytogenetic abnormalities are predictors of poor prognosis in multiple myeloma (MM). This paper aims to build and validate a...

    Thomas Van Den Berghe, Bert Verberckmoes, ... Koenraad Verstraete in Insights into Imaging

    Article Open access 10 April 2024
    

20. The emerging therapeutic landscape of relapsed/refractory multiple myeloma

    From a historic lens, treatment for patients with relapsed/refractory multiple myeloma (R/R MM) has advanced significantly since the advent of...

    Benjamin Tanenbaum, Timothy Miett, Shyam A. Patel in Annals of Hematology

    Article 03 December 2022